OrbusNeich’s COMBO dual therapy stent to be featured during AsiaPCR/SingLIVE 2013 symposium

273

OrbusNeich has announced that it will host a symposium featuring the COMBO Dual Therapy Stent at AsiaPCR/SingLIVE 2013 (24–26 January, Singapore) entitled “A new dimension to stent therapy.”

The symposium will take place on Thursday 24th January at 12.15pm in the Grand Ballroom, level 5, room 3, at the Marina Bay Sands, Sands Expo and Convention Centre, Singapore.

 


The event will be chaired by Aaron Wong of the National Heart Centre Singapore, and panel members will include Huay Cheem Tan of the National University Heart Centre Singapore (NUHCS), Teguh Santoso of Medistra Hospital, Indonesia, and Paul Ong of Tan Tock Seng Hospital, Singapore.

 


“With the COMBO dual therapy stent, we are most excited about the possibility of achieving better outcomes with less dependence on prolonged dual antiplatelet therapy,” said Mehran of the Mount Sinai Medical Center in New York. “The COMBO Stent, which combines the antirestenotic property of a drug eluting stent with a pro-healing endothelial progenitor cell capture technology, may help interventional cardiologists to better balance the risk of bleeding and ischaemic events.”

 


William Wijns of the Cardiovascular Center, Aalst, Belgium, added, “Delayed arterial healing following the placement of a drug eluting stent remains a risk factor for major complications such as thrombotic events. The COMBO dual therapy stent is designed to control neointimal growth while accelerating the natural healing process. Optical coherence tomography (OCT) is an imaging technology that may help us to better understand arterial healing.”